Survival Status of Esophageal Cancer Patients and its Determinants in Ethiopia: A Facility Based Retrospective Cohort Study.

Ethiopia cohort esophageal cancer prognostic determinants survival

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 13 08 2020
accepted: 18 12 2020
entrez: 4 3 2021
pubmed: 5 3 2021
medline: 5 3 2021
Statut: epublish

Résumé

Globally, the incidence and mortality due to esophageal cancer are increasing, particularly in low- and middle-income countries. Cancer of the esophagus is the eighth in incidence and seventh in cancer mortality in Ethiopia. A few studies have shown an increasing burden, however, little is known about the survival pattern and its determinants among esophageal cancer patients in Ethiopia. Therefore, we assessed the survival pattern and its determinants among esophageal cancer patients. We conducted a retrospective cohort study among 349 esophageal cancer patients who were diagnosed at or referred to Tikur Anbessa Specialized Hospital, Ethiopia from January 2010 to May 2017. Using an abstraction form, nurses who were working at the oncology department extracted the data from patient charts. To estimate and compare the probability of survival among covariate categories, we performed a Kaplan-Meier survival analysis with the log-rank test. To identify the prognostic determinants of survival, we performed a multivariable Cox proportional regression analysis. The median follow-up time was 32 months with interquartile range of 15 to 42. Overall, the median survival time after diagnosis with esophageal cancer was 4 months with one-, two- and three-year survival of 14.4, 6.3, and 2.4% respectively. In the multivariable Cox proportional hazards model, receiving chemotherapy [Adjusted Hazard Ratio (AHR)=0.36, 95%CI: 0.27-0.49], radiotherapy [AHR=0.38, 95%CI: 0.23-0.63] and surgery [AHR=0.70, 95%CI: 0.54-0.89] were statistically significant. In Ethiopia, esophageal cancer patients have a very low one-, two- and three-year survival. Despite a very low overall survival, patients who received either chemotherapy, radiotherapy or surgery showed a better survival compared with those who did not receive any treatment. Hence, it is essential to improve the survival of patients with esophageal cancer through early detection and timely initiation of the available treatment options.

Sections du résumé

BACKGROUND BACKGROUND
Globally, the incidence and mortality due to esophageal cancer are increasing, particularly in low- and middle-income countries. Cancer of the esophagus is the eighth in incidence and seventh in cancer mortality in Ethiopia. A few studies have shown an increasing burden, however, little is known about the survival pattern and its determinants among esophageal cancer patients in Ethiopia. Therefore, we assessed the survival pattern and its determinants among esophageal cancer patients.
METHODS METHODS
We conducted a retrospective cohort study among 349 esophageal cancer patients who were diagnosed at or referred to Tikur Anbessa Specialized Hospital, Ethiopia from January 2010 to May 2017. Using an abstraction form, nurses who were working at the oncology department extracted the data from patient charts. To estimate and compare the probability of survival among covariate categories, we performed a Kaplan-Meier survival analysis with the log-rank test. To identify the prognostic determinants of survival, we performed a multivariable Cox proportional regression analysis.
RESULTS RESULTS
The median follow-up time was 32 months with interquartile range of 15 to 42. Overall, the median survival time after diagnosis with esophageal cancer was 4 months with one-, two- and three-year survival of 14.4, 6.3, and 2.4% respectively. In the multivariable Cox proportional hazards model, receiving chemotherapy [Adjusted Hazard Ratio (AHR)=0.36, 95%CI: 0.27-0.49], radiotherapy [AHR=0.38, 95%CI: 0.23-0.63] and surgery [AHR=0.70, 95%CI: 0.54-0.89] were statistically significant.
CONCLUSIONS CONCLUSIONS
In Ethiopia, esophageal cancer patients have a very low one-, two- and three-year survival. Despite a very low overall survival, patients who received either chemotherapy, radiotherapy or surgery showed a better survival compared with those who did not receive any treatment. Hence, it is essential to improve the survival of patients with esophageal cancer through early detection and timely initiation of the available treatment options.

Identifiants

pubmed: 33659206
doi: 10.3389/fonc.2020.594342
pmc: PMC7917207
doi:

Types de publication

Journal Article

Langues

eng

Pagination

594342

Informations de copyright

Copyright © 2021 Hassen, Teka and Addisse.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Glob Oncol. 2018 Sep;4:1-10
pubmed: 30241222
Lancet Oncol. 2014 May;15(6):e205-12
pubmed: 24731885
PLoS One. 2015 Oct 08;10(10):e0140107
pubmed: 26448405
World J Gastroenterol. 2006 Jul 14;12(26):4185-90
pubmed: 16830371
J Cancer. 2019 Feb 26;10(6):1520-1527
pubmed: 31031862
Breast Cancer Res Treat. 2018 Jul;170(1):111-118
pubmed: 29479644
JAMA Oncol. 2017 Apr 1;3(4):524-548
pubmed: 27918777
Cancer Manag Res. 2018 Aug 14;10:2675-2682
pubmed: 30147366
Ann Transl Med. 2016 Jan;4(2):29
pubmed: 26889482
J Surg Oncol. 2005 Jun 15;90(4):209-19
pubmed: 15906363
Cancer. 2012 Sep 15;118(18):4372-84
pubmed: 22252462
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
JAMA Oncol. 2015 Jul;1(4):505-27
pubmed: 26181261
East Afr Med J. 2001 Dec;78(12):650-4
pubmed: 12199447
J Glob Oncol. 2018 Sep;4:1-11
pubmed: 30241262
Sci Rep. 2018 Mar 14;8(1):4522
pubmed: 29540708
J Glob Oncol. 2018 Nov;4:1-9
pubmed: 30398947
Curr Oncol. 2016 Dec;23(6):e546-e555
pubmed: 28050143
Ann Oncol. 2011 Nov;22(11):2349-2357
pubmed: 21378201
PLoS One. 2020 Mar 5;15(3):e0229854
pubmed: 32134996
Pan Afr Med J. 2019 May 31;33:73
pubmed: 31448035
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
World J Gastroenterol. 2019 Aug 21;25(31):4512-4533
pubmed: 31496629
Environ Health. 2011 Apr 05;10 Suppl 1:S7
pubmed: 21489217
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Arq Bras Cir Dig. 2016 Jul-Sep;29(3):138-141
pubmed: 27759773
Lancet Oncol. 2007 Sep;8(9):773-83
pubmed: 17714991

Auteurs

Hamid Yimam Hassen (HY)

Department of Public Health, Faculty of Medicine and Health Sciences, Mizan Tepi University, Mizan Teferi, Ethiopia.
Department of Primary and Interdisciplinary Care, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.

Mohammed Ahmed Teka (MA)

School of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

Adamu Addisse (A)

School of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

Classifications MeSH